SG11201810280YA - Spiro-lactam nmda receptor modulators and uses thereof - Google Patents
Spiro-lactam nmda receptor modulators and uses thereofInfo
- Publication number
- SG11201810280YA SG11201810280YA SG11201810280YA SG11201810280YA SG11201810280YA SG 11201810280Y A SG11201810280Y A SG 11201810280YA SG 11201810280Y A SG11201810280Y A SG 11201810280YA SG 11201810280Y A SG11201810280Y A SG 11201810280YA SG 11201810280Y A SG11201810280Y A SG 11201810280YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- compounds
- nmda receptor
- spiro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111011101111111111111111111111111111111111111111111111111111111111111111110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/201283 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: CO7D 487/10 (2006.01) A61P 25/00 (2006.01) A61K 31/407 (2006.01) (21) International Application Number: PCT/US2017/033323 (22) International Filing Date: 18 May 2017 (18.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/338,767 19 May 2016 (19.05.2016) US (71) Applicant: APTINYX INC. [US/US]; 1801 Maple Av- enue, Suite 4300, Evanston, IL 60201 (US). (72) Inventor: KHAN, M. Amin; 720 Oakton Street #3A, Evanston, IL 60202 (US). (74) Agent: BRODOWSKI, Michael et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = (81) =_ _ KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, — = TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every = (84) = = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = = _ _ TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, = KM, ML, MR, NE, SN, TD, TG). = Published: — with international search report (Art. 21(3)) Il en (54) Title: SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF ot) ei o (57) : Disclosed are compounds having enhanced potency in the modulation of NMDA receptor 1-1 Rd R 2 0 NH 2 activity. Such compounds can be used in the treatment of conditions such as depression and related ei N disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the IN R i N OH compounds, including intravenous formulations, are also disclosed. 1-1 0 ei o -_/ ( 1 ) C
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662338767P | 2016-05-19 | 2016-05-19 | |
PCT/US2017/033323 WO2017201283A1 (en) | 2016-05-19 | 2017-05-18 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810280YA true SG11201810280YA (en) | 2018-12-28 |
Family
ID=58779357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810280YA SG11201810280YA (en) | 2016-05-19 | 2017-05-18 | Spiro-lactam nmda receptor modulators and uses thereof |
Country Status (18)
Country | Link |
---|---|
US (2) | US9932347B2 (en) |
EP (1) | EP3458458B1 (en) |
JP (1) | JP6823083B2 (en) |
KR (1) | KR102128675B1 (en) |
CN (1) | CN109415372B (en) |
AU (1) | AU2017267708B2 (en) |
BR (1) | BR112018073663A2 (en) |
CA (1) | CA3024606C (en) |
CL (1) | CL2018003265A1 (en) |
CO (1) | CO2018013747A2 (en) |
EA (1) | EA201892657A1 (en) |
IL (1) | IL263045B (en) |
MX (1) | MX2018014202A (en) |
PE (1) | PE20190174A1 (en) |
PH (1) | PH12018502438A1 (en) |
SG (1) | SG11201810280YA (en) |
WO (1) | WO2017201283A1 (en) |
ZA (1) | ZA201807731B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101769999B1 (en) | 2008-09-18 | 2017-08-21 | 노오쓰웨스턴 유니버시티 | Nmda receptor modulators and uses thereof |
LT2951183T (en) | 2013-01-29 | 2019-05-27 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
MX2018014202A (en) * | 2016-05-19 | 2019-06-20 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof. |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
KR102462288B1 (en) | 2016-08-01 | 2022-11-01 | 앱티닉스 인크. | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof |
KR102503590B1 (en) | 2016-08-01 | 2023-02-24 | 앱티닉스 인크. | Spiro-lactam NMDA receptor modulators and uses thereof |
CA3031539C (en) | 2016-08-01 | 2023-11-28 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
CN109843889B (en) | 2016-08-01 | 2022-03-15 | 阿普廷伊克斯股份有限公司 | Spiro-lactam NMDA modulators and methods of using the same |
CA3031537A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
MX2020008106A (en) * | 2018-01-31 | 2020-09-25 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof. |
WO2019152681A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |
CN112204031A (en) | 2018-01-31 | 2021-01-08 | 阿普廷伊克斯股份有限公司 | Spiro-lactam NMDA receptor modulators and uses thereof |
WO2019152696A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
US20220259217A1 (en) | 2019-06-24 | 2022-08-18 | Naurex Inc. | Processes and intermediates for producing diazaspiro lactam compounds |
AU2020304001A1 (en) * | 2019-06-24 | 2022-01-27 | Naurex Inc. | Solid forms of tert-butyl (S)-2-((2S,3R) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
WO1992007561A1 (en) | 1990-10-30 | 1992-05-14 | Ss Pharmaceutical Co., Ltd. | Antiphlogistic and analgesic gel preparation |
US5168103A (en) | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
FR2692268B1 (en) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | New polypeptides having NMDA receptor activity, nucleic acids encoding these polypeptides and uses. |
SE9301667D0 (en) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | NEW USE |
US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
ATE283278T1 (en) | 1996-06-07 | 2004-12-15 | Astrazeneca Ab | PEPTIDE DERIVATIVES |
US5959075A (en) | 1996-08-02 | 1999-09-28 | Zymogenetics, Inc. | Testis-specific insulin homolog polypeptides |
US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
JP3955345B2 (en) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | New amino acid Daiji Harvein |
WO1999024584A1 (en) | 1997-11-12 | 1999-05-20 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
WO2000028090A2 (en) | 1998-11-12 | 2000-05-18 | Nyxis, Inc. | Diagnostic assay for cancer |
US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
WO2001036685A2 (en) | 1999-11-17 | 2001-05-25 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
JP2003521247A (en) | 2000-02-01 | 2003-07-15 | エージーワイ セラピューティクス インコーポレーテッド | Interaction of NMDA receptor with protein tyrosine phosphatase |
WO2001096606A2 (en) | 2000-06-14 | 2001-12-20 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
EP1296999A2 (en) | 2000-06-22 | 2003-04-02 | NYXIS NeuroTherapies, Inc. | Neuroactive peptides for treatment of hypoxia and related conditions |
GB0018272D0 (en) | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
AU2002236608A1 (en) | 2000-12-14 | 2002-06-24 | Nyxis Neurotherapies, Inc. | High throughput assay to detect inhibitors of the map kinase pathway |
AU2002248553A1 (en) | 2001-03-07 | 2002-09-24 | Cognetix, Inc | Linear y-carboxyglutamate rich conotoxins |
AU2002255705A1 (en) | 2001-03-12 | 2002-09-24 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
US20030022253A1 (en) | 2001-07-25 | 2003-01-30 | Nyxis Neurotherapies, Inc. | Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby |
ES2355157T3 (en) | 2002-07-05 | 2011-03-23 | Targacept, Inc. | N-ARILO DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE OF THE SAME. |
US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
WO2005014797A2 (en) | 2003-08-08 | 2005-02-17 | The Burnham Institute | P16 mediated regulation of nmda receptors |
WO2005020973A2 (en) | 2003-08-29 | 2005-03-10 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine |
GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
WO2006034196A1 (en) | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
CA2602950C (en) | 2005-03-24 | 2012-10-30 | Emory University | Methods for the treatment of central nervous system injury via a tapered administration of progesterone |
US7631994B2 (en) | 2005-07-11 | 2009-12-15 | Lights Of America, Inc. | Mounting system for a light fixture |
CA2620361C (en) | 2005-08-26 | 2014-10-14 | Wisconsin Alumni Research Foundation | Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same |
AR059224A1 (en) | 2006-01-31 | 2008-03-19 | Jerini Ag | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE |
WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
MX2009002921A (en) | 2006-09-15 | 2009-04-01 | Schering Corp | Azetidinone derivatives for the treatment of disorders of the lipid metabolism. |
JP2008188285A (en) | 2007-02-06 | 2008-08-21 | Bridgestone Corp | Back pad and vehicle seat |
CN101066945B (en) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | Process of synthesizing 3-substituted lactan compound |
CN101125817B (en) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | Method for synthesizing aldehyde substituted small ring amines compounds with high enantioselectivity and 3-substituted lactams compounds with optical activity |
WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
EP2257644B1 (en) | 2008-02-20 | 2015-06-24 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis of autism |
ES2461841T3 (en) | 2008-08-07 | 2014-05-21 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
KR101769999B1 (en) * | 2008-09-18 | 2017-08-21 | 노오쓰웨스턴 유니버시티 | Nmda receptor modulators and uses thereof |
WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
DE102009001460B4 (en) | 2009-03-11 | 2010-12-02 | Zf Friedrichshafen Ag | oilcontainer |
WO2011003064A2 (en) | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
RS53513B1 (en) | 2009-10-05 | 2015-02-27 | Northwestern University | Glyx-13 for use in a method of treating refractory depression |
US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
CN102933226A (en) | 2010-02-11 | 2013-02-13 | 西北大学 | Secondary structure stabilized nmda receptor modulators and uses thereof |
KR101692275B1 (en) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | Secondary structure stabilized nmda receptor modulators and uses thereof |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
KR20140043078A (en) | 2011-04-27 | 2014-04-08 | 노오쓰웨스턴 유니버시티 | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
US9293690B2 (en) | 2011-06-27 | 2016-03-22 | Koninklijke Philips N.V. | Ultrasound transducer assembly and method of manufacturing the same |
CN104109161B (en) | 2011-07-27 | 2016-08-17 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-substituted aniline) pyrimidine derivatives is used for treating cancer as EGFR modulator |
EP2951182B1 (en) * | 2013-01-29 | 2020-03-18 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
EP2951185B1 (en) | 2013-01-29 | 2016-12-21 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
LT2951183T (en) * | 2013-01-29 | 2019-05-27 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
PE20151437A1 (en) * | 2013-01-29 | 2015-10-10 | Naurex Inc | SPIRO-LACTAMA NMDA RECEIVER MODULATORS AND THEIR USES |
US9738650B2 (en) | 2013-01-29 | 2017-08-22 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
MX2018014202A (en) * | 2016-05-19 | 2019-06-20 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof. |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
-
2017
- 2017-05-18 MX MX2018014202A patent/MX2018014202A/en unknown
- 2017-05-18 JP JP2018560848A patent/JP6823083B2/en active Active
- 2017-05-18 KR KR1020187036821A patent/KR102128675B1/en active IP Right Grant
- 2017-05-18 PE PE2018003075A patent/PE20190174A1/en not_active Application Discontinuation
- 2017-05-18 CN CN201780040033.0A patent/CN109415372B/en active Active
- 2017-05-18 AU AU2017267708A patent/AU2017267708B2/en not_active Ceased
- 2017-05-18 BR BR112018073663-5A patent/BR112018073663A2/en not_active Application Discontinuation
- 2017-05-18 CA CA3024606A patent/CA3024606C/en active Active
- 2017-05-18 EP EP17726169.0A patent/EP3458458B1/en active Active
- 2017-05-18 SG SG11201810280YA patent/SG11201810280YA/en unknown
- 2017-05-18 EA EA201892657A patent/EA201892657A1/en unknown
- 2017-05-18 WO PCT/US2017/033323 patent/WO2017201283A1/en unknown
- 2017-06-30 US US15/638,669 patent/US9932347B2/en active Active
- 2017-12-04 US US15/830,378 patent/US10196401B2/en active Active
-
2018
- 2018-11-15 IL IL263045A patent/IL263045B/en unknown
- 2018-11-16 ZA ZA2018/07731A patent/ZA201807731B/en unknown
- 2018-11-16 CL CL2018003265A patent/CL2018003265A1/en unknown
- 2018-11-19 PH PH12018502438A patent/PH12018502438A1/en unknown
- 2018-12-18 CO CONC2018/0013747A patent/CO2018013747A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2019516735A (en) | 2019-06-20 |
EA201892657A1 (en) | 2019-05-31 |
US20170334922A1 (en) | 2017-11-23 |
CL2018003265A1 (en) | 2019-01-25 |
IL263045A (en) | 2018-12-31 |
IL263045B (en) | 2021-07-29 |
US20180093994A1 (en) | 2018-04-05 |
KR102128675B1 (en) | 2020-06-30 |
CO2018013747A2 (en) | 2019-01-18 |
ZA201807731B (en) | 2019-08-28 |
BR112018073663A2 (en) | 2019-04-30 |
CA3024606C (en) | 2019-09-03 |
MX2018014202A (en) | 2019-06-20 |
US10196401B2 (en) | 2019-02-05 |
CA3024606A1 (en) | 2017-11-23 |
EP3458458B1 (en) | 2020-11-04 |
PH12018502438A1 (en) | 2019-09-09 |
CN109415372B (en) | 2021-01-15 |
CN109415372A (en) | 2019-03-01 |
PE20190174A1 (en) | 2019-02-01 |
AU2017267708A1 (en) | 2018-12-06 |
KR20190010613A (en) | 2019-01-30 |
US9932347B2 (en) | 2018-04-03 |
JP6823083B2 (en) | 2021-01-27 |
WO2017201283A1 (en) | 2017-11-23 |
AU2017267708B2 (en) | 2020-02-20 |
EP3458458A1 (en) | 2019-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201811559WA (en) | Cancer treatment combinations | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases |